Because administering COMP-Ang1 protein may result in the suppression of hemorrhagic transformation and cerebral edema, Ang1 can be considered to be a promising target molecule for vasoprotective treatment to prevent the BBB damage that accompanies tPA treatment. The gene discussed is COMP; the disease is brain edema.